You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Kynos Therapeutics targets inflammation-driven illness

Kynos Therapeutics has announced major financing to support its lead KMO inhibitor (KMOi) programme through phase 1 clinical trials. It will also progress its innovative pipeline of first-in-class KMOi across key indications in inflammation, immunity and metabolism.